Pituitary and SARS CoV-2: An unremitting conundrum

Area of Science:

• Endocrinology
• Virology
• Immunology

Background:

• The endocrine system, particularly the pituitary gland, is increasingly recognized as a target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
• COVID-19 infection can lead to both acute and delayed pituitary dysfunction, including hypopituitarism, pituitary apoplexy, hypophysitis, and disturbances in arginine vasopressin secretion.
• Patients with pre-existing pituitary conditions such as acromegaly, Cushing's disease, and hypopituitarism may face elevated risks of severe COVID-19 complications.

Purpose of the Study:

• To review and summarize current evidence on the effects of COVID-19 and its vaccination on pituitary function.
• To analyze the impact on both individuals with normal pituitary function and those with pre-existing pituitary pathologies.

Main Methods:

• Systematic review of existing literature and data analysis.
• Evaluation of reported cases of pituitary dysfunction in COVID-19 patients.
• Assessment of biochemical control in patients with pituitary pathologies during the pandemic.

Main Results:

• Various pituitary dysfunctions, including hypopituitarism and diabetes insipidus, have been reported in association with COVID-19.
• While clinical systems were impacted, patients with certain pituitary pathologies generally maintained biochemical control.
• The long-term effects of COVID-19 and vaccination on pituitary function are still under investigation.

Conclusions:

• COVID-19 poses a significant threat to pituitary health, necessitating careful monitoring of affected individuals.
• Despite challenges, effective management strategies appear to preserve biochemical control in many patients with pituitary conditions.
• Continued research is crucial to fully understand the multifaceted impact of SARS-CoV-2 on the pituitary gland.